Floatz logo

Peginterferon

Nonalcoholic Steatohepatitis

Charles University, Czech RepublicN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB
Metformin
Altimmune, Inc.
Phase 4BBB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Peginterferon is also rated in:

hepatitis C virus infectionDormant
BBB
Indicative ·
75 / 100
View asset →
Nonalcoholic Fatty Liver DiseaseDormant
BB
Indicative ·
65 / 100
View asset →
Chronic Hepatitis bDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →